Cefotaxim MIP 1 g Norge - norsk - Statens legemiddelverk

cefotaxim mip 1 g

mip pharma gmbh - cefotaksimnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g

Imatinib Koanaa Den europeiske union - norsk - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastiske midler - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. pasienter som har en lav eller svært lav risiko for tilbakefall bør ikke får adjuvant behandling. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. bortsett fra i nydiagnostisert kronisk fase kml, det er ingen kontrollerte studier som viser en klinisk nytte eller økt overlevelse for disse sykdommer.

Onduarp Den europeiske union - norsk - EMA (European Medicines Agency)

onduarp

boehringer ingelheim international gmbh - telmisartan - hypertensjon - sirkulasjonssystem - behandling av essensiell hypertensjon hos voksne:legg på therapyonduarp er indisert hos voksne hvis blodtrykket ikke er tilstrekkelig kontrollert på amlodipine. erstatning therapyadult pasienter som mottar telmisartan og amlodipine fra separate tabletter kan i stedet få tabletter av onduarp inneholder den samme komponenten doser.

Cinacalcet Aristo 30 mg Norge - norsk - Statens legemiddelverk

cinacalcet aristo 30 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 30 mg

Cinacalcet Aristo 60 mg Norge - norsk - Statens legemiddelverk

cinacalcet aristo 60 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 60 mg

Cinacalcet Aristo 90 mg Norge - norsk - Statens legemiddelverk

cinacalcet aristo 90 mg

aristo pharma gmbh - cinacalcethydroklorid - tablett, filmdrasjert - 90 mg

Idelvion Den europeiske union - norsk - EMA (European Medicines Agency)

idelvion

csl behring gmbh - albutrepenonacog alfa - hemofili b - antihemoragika - behandling og profylakse av blødning hos pasienter med hemofili b (medfødt faktor ix-mangel).

Adynovi Den europeiske union - norsk - EMA (European Medicines Agency)

adynovi

baxalta innovations gmbh - rurioctocog alfa pegol - hemofili a - antihemoragika - behandling og profylakse av blødning hos pasienter 12 år og over med hemofili a (medfødt faktor viii-mangel).

Entocort 3 mg Norge - norsk - Statens legemiddelverk

entocort 3 mg

tillotts pharma gmbh - budesonid - depotkapsel, hard - 3 mg

Tadalafil AOP 20 mg Norge - norsk - Statens legemiddelverk

tadalafil aop 20 mg

aop orphan pharmaceuticals gmbh - tadalafil - tablett, filmdrasjert - 20 mg